Cargando…

Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau

Background: Chronic acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis predominantly affecting the distal phalanges of the fingers and toes. The disease manifests by pustular rash with marked infiltration, fissures, and often results into severe dystrophy of nail plates....

Descripción completa

Detalles Bibliográficos
Autores principales: Smirnova, LM, Vertieva, E Yu, Olisova, O Yu, Anpilogova, EM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535620/
https://www.ncbi.nlm.nih.gov/pubmed/31190732
http://dx.doi.org/10.2147/BTT.S199100
_version_ 1783421587280625664
author Smirnova, LM
Vertieva, E Yu
Olisova, O Yu
Anpilogova, EM
author_facet Smirnova, LM
Vertieva, E Yu
Olisova, O Yu
Anpilogova, EM
author_sort Smirnova, LM
collection PubMed
description Background: Chronic acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis predominantly affecting the distal phalanges of the fingers and toes. The disease manifests by pustular rash with marked infiltration, fissures, and often results into severe dystrophy of nail plates. ACH is refractory to most of psoriasis standard of care (SOC) therapies. Objective: The objective of this study is to assess the prospects of secukinumab therapy of ACH based on current clinical observation. Methods: We observed a female patient with ACH. Number of SOC treatments were applied in that case including local PUVA therapy, systemic retinoids, methotrexate, and biologic agents. Result: Secukinumab, a IL-17 inhibitor, demonstrated pronounced clinical effect in the case of ACH refractory to other SOC therapies. Conclusion: IL-17 inhibition provided by secukinumab was linked to clinically meaningful improvement in the heavily pretreated ACH. Further exploration and clinical studies may be important to provide more data on secukinumab effects in ACH.
format Online
Article
Text
id pubmed-6535620
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65356202019-06-12 Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau Smirnova, LM Vertieva, E Yu Olisova, O Yu Anpilogova, EM Biologics Case Report Background: Chronic acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis predominantly affecting the distal phalanges of the fingers and toes. The disease manifests by pustular rash with marked infiltration, fissures, and often results into severe dystrophy of nail plates. ACH is refractory to most of psoriasis standard of care (SOC) therapies. Objective: The objective of this study is to assess the prospects of secukinumab therapy of ACH based on current clinical observation. Methods: We observed a female patient with ACH. Number of SOC treatments were applied in that case including local PUVA therapy, systemic retinoids, methotrexate, and biologic agents. Result: Secukinumab, a IL-17 inhibitor, demonstrated pronounced clinical effect in the case of ACH refractory to other SOC therapies. Conclusion: IL-17 inhibition provided by secukinumab was linked to clinically meaningful improvement in the heavily pretreated ACH. Further exploration and clinical studies may be important to provide more data on secukinumab effects in ACH. Dove 2019-05-20 /pmc/articles/PMC6535620/ /pubmed/31190732 http://dx.doi.org/10.2147/BTT.S199100 Text en © 2019 Smirnova et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Smirnova, LM
Vertieva, E Yu
Olisova, O Yu
Anpilogova, EM
Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title_full Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title_fullStr Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title_full_unstemmed Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title_short Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title_sort outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of hallopeau
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535620/
https://www.ncbi.nlm.nih.gov/pubmed/31190732
http://dx.doi.org/10.2147/BTT.S199100
work_keys_str_mv AT smirnovalm outcomesofvarioustypesoftherapyinpatientswithtreatmentresistantacrodermatitiscontinuaofhallopeau
AT vertievaeyu outcomesofvarioustypesoftherapyinpatientswithtreatmentresistantacrodermatitiscontinuaofhallopeau
AT olisovaoyu outcomesofvarioustypesoftherapyinpatientswithtreatmentresistantacrodermatitiscontinuaofhallopeau
AT anpilogovaem outcomesofvarioustypesoftherapyinpatientswithtreatmentresistantacrodermatitiscontinuaofhallopeau